Stable emulsions of bacterial antigens
The present invention is based on the discovery of new and advantageous properties of a class of known polymeric emulsifiers. The emulsifier class was found to be resistant to degradation by crude bacterial antigen preparations, which degradation caused emulsion instability when using prior art emulsifiers. This allows the formulation of safe, stable, and effective vaccines based on these emulsions of oil and water comprising such bacterial antigens. The polymeric emulsifier is a block copolymer having a general formula A-B-A in which component B is the divalent residue of a water-soluble polyalkylene glycol and component A is the residue of an oil-soluble complex monocarboxylic acid. Preferred emulsifier is a PEG-30-di-(polyhydroxystearate).
1. A vaccine for the protection of a human or animal target against infection or disease caused by a bacterium, comprising an emulsion, the emulsion comprising an oil phase, an aqueous phase, an emulsifier and non-live bacterial antigen,
wherein the emulsifier is a polymeric emulsifier which is a block copolymer having a general formula A-B-A in which component B is the divalent residue of a water-soluble polyalkylene glycol and component A is the residue of an oil-soluble complex monocarboxylic acid, and
wherein the non-live bacterial antigen comprises a bacterial esterase.
2. The vaccine of claim 1 , wherein the vaccine is for the protection of an animal target.
3. A method of vaccinating a human or animal target against infection or disease caused by a bacterium, comprising administering to said target the vaccine of claim 1 .
4. A method of vaccinating an animal target against infection or disease caused by a bacterium, comprising administering the vaccine of claim 2 to said animal target.
5. The vaccine of claim 2 , wherein the animal target is a fish.
6. A method of vaccinating a fish against infection or disease caused by a bacterium, comprising administering the vaccine of claim 5 to said fish.
7. The vaccine of claim 1 , wherein component A is a polyhydroxystearic acid, and component B is a polyethylene glycol.
8. The vaccine of claim 1 , wherein the polymeric emulsifier is a PEG-30-di-(polyhydroxystearate).
9. The vaccine of claim 1 , wherein the non-live bacterial antigen comprises an inactivated whole bacterial culture, or part of an inactivated bacterial culture.
10. The vaccine of claim 9 , wherein the part of an inactivated bacterial culture is selected from any of: a pellet, supernatant, concentrate, dialysate, extract, sonicate, lysate or fraction of a culture inactivated bacterial culture.
11. The vaccine of claim 9 , wherein the non-live bacterial antigen is selected from the group consisting of: an inactivated bacterial cell, an intact inactivated bacterial cell or a damaged inactivated bacterial cell.
12. The vaccine of claim 1 , wherein the non-live bacterial antigen comprises a Aeromonas salmonicida and/or Moritella viscosa non-live bacterial antigen.